Safety First Trust Principal-Protected Certificates Linked TO A U.S.-Europe-Japan Basket (AMEX:ATA)
Historical Stock Chart
From Jun 2019 to Jun 2024
Apogee Technology, Inc. (AMEX: ATA), an emerging micro-systems and
nanotechnology company that designs, develops and commercializes medical
devices and sensor products, announced today that it has filed five U.S.
provisional patent applications related to its PyraDerm™
intradermal drug delivery system. Three of the new patent applications
pursue the protection of methods and compositions for specific
biomedical applications and two of the patent applications pertain to
novel drug delivery formulations for biomedical devices and associated
microfabrication processes.
Dr. Alexander K. Andrianov, Apogee’s Vice
President of Research & Development said, “This
is a significant milestone in the development of our intellectual
property position. These new filings expand the portfolio of patents and
patent applications related to our micro needle drug delivery
technology. We are now focusing our development resources on the in vivo
validation of this technology and its introduction to strategic partners.”
About Apogee Technology, Inc.
Apogee Technology designs, develops and commercializes proprietary
medical device and sensor products using its MEMS and nanotechnology for
the medical, automotive, industrial and consumer markets. The Company is
developing its PyraDerm™ solution for enhanced
intradermal drug delivery and has introduced a family of pressure
sensors under the Sensilica™ brand. Apogee’s
goal is to provide value-added and cost-savings solutions for our
customers and, in so doing, to become a global leader in the sensor and
medical device fields. For more information please visit our web site
at: http://www.apogeemems.com.
PyraDerm™ and Sensilica™
are trademarks of Apogee Technology, Inc. All other product names noted
herein may be trademarks of their respective holders. Certain statements
made herein that use the words "anticipate," "hope," "estimate,"
"project," "intend," "plan," "expect," "believe" and similar expressions
are intended to identify forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve known and unknown risks and
uncertainties, which could cause the actual results, performance or
achievements of the Company to be materially different from those that
may be expressed or implied. Please refer to the company's risk factors
as set forth in the Company's filings with the Securities and Exchange
Commission, including its reports on Forms 10-KSB and 10-QSB.
Apogee Technology, Inc. (AMEX: ATA), an emerging micro-systems and
nanotechnology company that designs, develops and commercializes
medical devices and sensor products, announced today that it has filed
five U.S. provisional patent applications related to its PyraDerm(TM)
intradermal drug delivery system. Three of the new patent applications
pursue the protection of methods and compositions for specific
biomedical applications and two of the patent applications pertain to
novel drug delivery formulations for biomedical devices and associated
microfabrication processes.
Dr. Alexander K. Andrianov, Apogee's Vice President of Research &
Development said, "This is a significant milestone in the development
of our intellectual property position. These new filings expand the
portfolio of patents and patent applications related to our micro
needle drug delivery technology. We are now focusing our development
resources on the in vivo validation of this technology and its
introduction to strategic partners."
About Apogee Technology, Inc.
Apogee Technology designs, develops and commercializes proprietary
medical device and sensor products using its MEMS and nanotechnology
for the medical, automotive, industrial and consumer markets. The
Company is developing its PyraDerm(TM) solution for enhanced
intradermal drug delivery and has introduced a family of pressure
sensors under the Sensilica(TM) brand. Apogee's goal is to provide
value-added and cost-savings solutions for our customers and, in so
doing, to become a global leader in the sensor and medical device
fields. For more information please visit our web site at:
http://www.apogeemems.com.
PyraDerm(TM) and Sensilica(TM) are trademarks of Apogee
Technology, Inc. All other product names noted herein may be
trademarks of their respective holders. Certain statements made herein
that use the words "anticipate," "hope," "estimate," "project,"
"intend," "plan," "expect," "believe" and similar expressions are
intended to identify forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve known and unknown risks and
uncertainties, which could cause the actual results, performance or
achievements of the Company to be materially different from those that
may be expressed or implied. Please refer to the company's risk
factors as set forth in the Company's filings with the Securities and
Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.